Search Results
Your search for it matches 15526 pages
Showing 14901 - 14950BPA Stimulates Growth of Breast Cancer Cells, Diminishes Effect of Treatment
Bisphenol A (BPA), a chemical commonly used in plastics, appears to increase the proliferation of breast cancer cells, according to Duke Medicine researchers presenting at ICE/ENDO 2014, the annual joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago. The ...
New Tool Predicts Financial Pain for Cancer Patients
In an online report in the journal Cancer, a team of University of Chicago cancer specialists have described the first tool—11 questions, assembled and refined from conversations with more than 150 patients with advanced cancer—to measure a patient’s risk for, and ability to...
No Improvement in Long-Term Outcomes With Extended Colectomy for Sporadic Colorectal Cancer in Patients Younger Than Age 50
Extended colectomy in patients with sporadic colorectal cancer who were younger than age 50, in comparison with segmental resection, did not improve the risk of tumor recurrence or disease-free survival, according to the results of a retrospective study presented by Klos et al in the Journal of...
Development of Orteronel for Prostate Cancer Voluntarily Discontinued by Takeda
Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700), an investigational oral, nonsteroidal, selective inhibitor of 17,20-lyase, for prostate cancer. The decision follows the results of two phase III...
Racial Disparities in Sentinel Lymph Node Biopsy in Women With Breast Cancer
A study by Black et al from The University of Texas MD Anderson Cancer Center, Houston, found that the use of sentinel lymph node biopsy to stage early breast cancer increased in both black and white women from 2002 to 2007, but the rates remained lower in black than white patients, a disparity...
Diversity of Intestinal Tract Bacteria Associated With Mortality Outcomes After Stem Cell Transplant, Study Shows
New research published online in Blood suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival. Potential Connections Previous studies have shown that the intensive treatment...
Surgical Treatment Delay May Not Result in Worse Outcomes in Patients With Colon Cancer
A “reasonable” delay prior to surgery for colon cancer may not result in worse outcomes, according to the results of a retrospective study presented by Amri et al in the Annals of Surgical Oncology. Flexibility in scheduling surgery may lead to an improvement in the quality and safety...
Survey Finds Booming E-Cigarette Online Market
Researchers at the University of California, San Diego, School of Medicine have completed the first comprehensive survey of e-cigarettes for sale online, and the results, they believe, underscore the complexity in regulating the rapidly growing market for the electronic nicotine delivery devices....
Priming Pancreatic Cancer Cells With a Vaccine May Allow Them to Respond to Immunotherapy
Pancreatic ductal adenocarcinoma is considered a “nonimmunogenic” neoplasm and does not typically respond to immunotherapy, in part due to a complex tumor microenvironment that provides a formidable barrier to immune infiltration and function. A new study by Lutz et al has found that by ...
Study Identifies Two Proteins as Markers of Response to Neoadjuvant Chemotherapy for Ovarian Cancer
A study by researchers from Danbury Hospital Biomedical Research Institute in Connecticut has found that patients with ovarian cancer who relapse shortly after neoadjuvant chemotherapy to shrink their tumor prior to surgery have high levels of expression of HGF and c-Met proteins. The...
Stage Migration and Dilution of Higher Stages With PET in Head and Neck Cancer in a Managed Care Setting
A study reported in JAMA Otolaryngology-Head & Neck Surgery by VanderWalde and colleagues suggests that increasing use of positron emission tomography (PET) for diagnosis and staging of head and neck cancer has resulted in considerable stage migration characterized by dilution of higher stages...
Lung-MAP Launches: First Precision Medicine Trial From National Clinical Trials Network
A unique public-private collaboration among the National Cancer Institute (NCI), SWOG Cancer Research, Friends of Cancer Research, the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global...
Phase III Trial of Adding Figitumumab to Chemotherapy in Advanced Nonadenocarcinoma NSCLC Stopped Early for Futility and Increased Harm
In the first phase III trial assessing the combination of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor with chemotherapy as first-line treatment for advanced nonadenocarcinoma non–small cell lung cancer (NSCLC), the addition of the fully human immunoglobulin G2 monoclonal...
FDA Approves Magnetic Resonance Contrast Agent for Evaluation of Breast Cancer
The U.S. Food and Drug Administration has approved a new indication for gadobutrol (Gadavist) injection for intravenous use with magnetic resonance imaging (MRI) of the breast to assess the presence and extent of malignant breast disease. The approval is based on priority review of two multicenter...
Survivors of Childhood Cancers Experience Frequent Hospitalizations Years After Cancer Treatment
Childhood and adolescent cancer survivors often face ongoing health problems that require frequent and long hospital stays many years after their cancer diagnosis and treatment, according to a new study by Kirchhoff et al published in Cancer Epidemiology, Biomarkers & Prevention. Survivors of...
Mammography Has Led to Fewer Late-Stage Breast Cancers, Study Finds
In the past 30 years, since mammography was introduced, late-stage breast cancer incidence has decreased by 37%, a new study published in Cancer has found. The analysis by Helvie et al took into account an observed underlying trend of increased breast cancer incidence present since the 1940s....
Study Identifies Genetic Variant Associated With Increased Risk of Invasive Lobular Breast Cancer
There may be significant genomic differences between patients with invasive lobular breast cancer and those with invasive ductal breast cancer, according to the results of a study presented by Sawyer et al in PLOS Genetics. This finding may lead to further insights into the biology of lobular...
ASCO 2014: Stopping Statins Is Safe and Can Improve Quality of Life for Patients With Cancer Near the End of Life
Stopping statin therapy is safe for patients with cancer who have a life expectancy of less than 1 year, according to a randomized study reported at the 2014 ASCO Annual Meeting in Chicago (Abstract LBA9514). Discontinuing statins did not shorten survival and provided a number of important...
ASCO 2014: Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor–Negative Breast Cancer
Adding goserelin (Zoladex) to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor–negative breast cancer, according to findings from a federally funded phase III clinical trial. In the S0230/POEMS study, reported at the 2014...
ASCO 2014: Starting Palliative Care Support for Family Caregivers at the Time of Cancer Diagnosis Improves Quality of Life
Introducing a palliative care support program for caregivers of patients with advanced cancer at or near the time patients are diagnosed provides greater benefits than delayed palliative care services, according to results of the ENABLE III study reported at the 2014 ASCO Annual Meeting in Chicago...
Initial Treatment of Ductal Carcinoma in Situ May Affect Subsequent Treatment of Tumor Recurrences After Surgery
The use of radiotherapy for the index ductal carcinoma in situ (DCIS) may affect subsequent treatment of tumor recurrences and complications after breast-conserving surgery, reported Greenberg et al in the Annals of Surgical Oncology. Based on the results of this retrospective cohort study, the...
ASCO 2014: Women With Breast Cancer and Bone Metastasis Can Safely Scale Back Frequency of Zoledronic Acid Dosing
Findings from a phase III randomized study suggest that women with breast cancer and bone metastasis who have received at least nine doses of zoledronic acid over the previous year can safely scale back dosing from every 4 weeks to every 12 weeks without compromising the effectiveness of the...
ASCO 2014: Lower-Dose Radiation May Reduce Long-Term Side Effects Without Compromising Survival in Certain HPV-Positive Head and Neck Cancers
According to a phase II study, customizing radiation doses based on response to induction chemotherapy and other prognostic factors may allow lower doses of radiation therapy to be administered to some patients with human papillomavirus (HPV)-positive oropharyngeal cancer without compromising...
ASCO 2014: Ipilimumab/Nivolumab Combination Achieves Long-Term Survival for Patients With Advanced Melanoma
Concurrent treatment with ipilimumab (Yervoy) and nivolumab resulted in a 2-year survival rate of 79% for patients with advanced melanoma. “While this is a small trial, that is very impressive 2-year survival data,” noted Mario Sznol, MD, at a press briefing on progress in immunotherapy ...
ASCO 2014: Adjuvant Ipilimumab Significantly Improves Recurrence-Free Survival in Patients With High-Risk Stage III Melanoma
Adjuvant therapy with ipilimumab (Yervoy) for patients with high-risk stage III melanoma significantly improved recurrence-free survival, the primary endpoint of the phase III EORTC 18071/CA 184-029 study. Patients randomly assigned to receive ipilimumab had a 9-month absolute improvement in...
Smokers With BRCA2 Mutation Have Increased Risk of Developing Lung Cancer
Around a quarter of smokers who carry a mutation in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals. Scientists described a previously unknown link between lung cancer and a particular BRCA2 mutation, which occurs in around 2% of...
Adjuvant! Online Performs Poorly in Older Patients With Breast Cancer in Dutch Study
In a Dutch population-based study reported in The Lancet Oncology, de Glas et al found that the Adjuvant! Online prediction tool performed poorly in older patients with early-stage breast cancer, significantly overestimating or underestimating overall survival depending on comorbidity...
Ibrutinib Resistance Mutations Identified in CLL Patients
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase that was recently approved for treatment of chronic lymphocytic leukemia (CLL) patients who have received at least one prior therapy. A small proportion of CLL patients have been observed to relapse during ibrutinib treatment, ...
ASCO 2014: Cediranib Plus Olaparib Significantly Increases Progression-Free Survival in Women With Recurrent Ovarian Cancer
The combination of two investigational oral drugs, the PARP inhibitor olaparib and the antiangiogenic drug cediranib, significantly extended progression-free survival and increased the overall response rate compared to olaparib alone in a phase II study among women with recurrent,...
ASCO 2014: Lenvatinib Yields High Response Rates, Delays Progression in Patients With Radioiodine-Resistant Differentiated Thyroid Cancer
A phase III, multicenter, double-blind, placebo-controlled study found that the oral targeted drug lenvatinib is highly effective among patients with differentiated thyroid cancer resistant to standard radioiodine therapy. “The main result is an extraordinary improvement in progression-free...
ASCO 2014: Adding Lapatinib to Adjuvant Trastuzumab Does Not Improve Outcomes in Early-Stage HER2-Positive Breast Cancer
A large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), found no statistically significant differences in 4-year disease-free survival among women with early HER2-positive breast cancer who received adjuvant treatment that combined the HER2-targeted drugs...
ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
ASCO 2014: Ibrutinib Significantly Delays Disease Progression and Extends Survival in Relapsed CLL
Early findings from the phase III RESONATE study indicate that ibrutinib (Imbruvica) produces durable tumor responses and marked improvement in survival over standard ofatumumab (Arzerra) for patients with relapsed chronic lymphocytic leukemia (CLL). “With ibrutinib, about 80% of patients...
ASCO 2014: Second-Line Treatment With Ramucirumab Plus Standard Docetaxel Extends Overall Survival in Advanced Lung Cancer
Patients with stage IV non–small cell lung cancer (NSCLC) who relapsed after initial platinum-based therapy experienced extended overall survival with a combination of the antiangiogenic agent ramucirumab (Cyramza) and standard chemotherapy with docetaxel, compared to patients receiving...
ASCO 2014: Investigational Anti–PD-L1 Antibody Demonstrates Promising Activity in Certain Patients With Metastatic Bladder Cancer
In a phase I study, the investigational anti–programmed death-ligand 1 (PD-L1) monoclonal antibody MPDL3280A demonstrated promising overall response rates in patients with previously treated metastatic urothelial bladder cancer whose tumors were characterized as PD-L1–positive. The ...
ASCO 2014: Women With BRCA Mutations Report Significant Side Effects Following Risk-Reducing Salpingo-Oophorectomy
The majority of women with BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following risk-reducing salpingo-oophorectomy, according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine ...
ASCO 2014: Men Who Receive Radiation Therapy for Prostate Cancer Have Increased Long-Term Risk of Bladder or Rectal Cancer
Men with prostate cancer generally have an excellent prognosis, but questions remain about the risk of second primary malignancies after initial therapy for localized disease. According to a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 5034), although the overall risk of ...
Study Identifies Risk of Chemotherapy-Related Hospitalization for Early-Stage Breast Cancer Patients
Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early-stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. The retrospective study, reported in the Journal of Clinical Oncology by...
ASCO Guideline Update Recommends Tamoxifen for Up to 10 Years for Women With Nonmetastatic Hormone Receptor–Positive Breast Cancer
The American Society of Clinical Oncology (ASCO) has issued an update to its clinical practice guideline on the use of adjuvant endocrine therapy for women with stage I to III hormone receptor–positive breast cancer. The guideline was published in the Journal of Clinical Oncology. Duration...
No Apparent Benefit of Adding Cetuximab to Gemcitabine Plus Oxaliplatin in Advanced Biliary Tract Cancer
Gemcitabine plus a platinum agent is standard treatment in advanced biliary cancer. In the phase II open-label noncomparative BINGO trial, reported in The Lancet Oncology, Malka et al found no apparent benefit of adding the EGFR inhibitor cetuximab (Erbitux) to gemcitabine/oxaliplatin in first-line ...
Gene Mutation Found for Aggressive Form of Pancreatic Cancer
Researchers have identified a mutated gene common to adenosquamous carcinoma tumors, the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer. The findings by Liu et al are published in Nature Medicine. Pancreatic cancer is the fourth leading...
More Toxicity Associated With Addition of Sorafenib to Yttrium-90 Radioembolization Prior to Liver Transplantation
The addition of sorafenib (Nexavar) to yttrium-90 radioembolization was associated with higher rates of biliary complications and potentially more acute rejections prior to transplantation in patients with hepatocellular carcinoma, according to the results of a prospective randomized pilot study....
Percentage Dense Area Stronger Than Absolute Dense Area as Mammography Risk Factor for Breast Cancer
In a meta-analysis reported in the Journal of the National Cancer Institute, Pettersson et al found that percentage dense area on breast mammography is a stronger predictor of breast cancer than absolute dense area. An inverse association of absolute nondense area and risk was also observed. The...
Majority of Women Undergoing Contralateral Prophylactic Mastectomy Have No Major Risk Factors for Developing Cancer in Both Breasts
Patients deciding to undergo contralateral prophylactic mastectomy as part of initial treatment for breast cancer is a growing challenge in the management of the disease. Removing the unaffected breast has not been shown to increase survival, and the more aggressive procedure is associated with...
Supportive Tumor Tissue Surrounding Cancer Cells Hinders Pancreatic Cancer Progression, Preclinical Study Reports
Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center reported in the journal Cancer Cell. “This supportive tissue that’s...
Study Uses Comprehensive Genomic Tumor Testing to Match Lung Cancer Patients With Targeted Therapies
In a recent study by the Lung Cancer Mutation Consortium (LCMC), investigators incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64% of tumors from patients in this study. According to data from this study...
Study Reveals More Than One-Third of Patients With ‘Low-Risk’ Prostate Cancer on Conventional Biopsy Have More Aggressive Tumors on Targeted Biopsy
According to a new study by researchers at the University of California, Los Angeles, selection of men for active surveillance for prostate cancer should be based not on conventional biopsy, but on a new, imaging-guided targeted prostate biopsy. The new biopsy method is now a routine part of the...
No Overall Survival Improvement With Ipilimumab After Radiotherapy in Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel
In a phase III trial (CA184-043) reported in The Lancet Oncology, Kwon et al assessed the effects of adding ipilimumab (Yervoy) after radiotherapy in patients with metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy. The investigators found no improvement...
Study Suggests Less Frequent Cardiac Screening May Be Preferable for Survivors of Childhood Cancer
One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure found improved health outcomes but suggested that less frequent screening than currently recommended may yield similar clinical benefit. Researchers ...
Early Study Shows Improved Survival With Radioimmunotherapy/Gemcitabine Combination in Patients With Advanced Pancreatic Ductal Cancer
A randomized phase Ib study of a combination of low radiosensitizing doses of gemcitabine and fractionated doses of 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic ductal cancer who had received at least two prior systemic therapies, has found a significant survival advantage in...
